Skip to content
Plcoskin logo — Plcoskin is a MedTech company specializing in reconstructive...

Plcoskin

Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare.

Founded 2017 Korea South Korea South 1 employees Series B Total: $900.00M Biopharma, Biotechnology +1

General Information

Company Name Plcoskin
Founded Year 2017
Location Korea South Korea South
Founders / Decision Makers
Team member
Employees 1
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Plcoskin. To contact Plcoskin, visit plcoskin.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Plcoskin compare?

A PDF of Plcoskin and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Plcoskin soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Plcoskin

Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that is commonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds. Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds. In addition to their medical devices, Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Available in the US, Europe, Taiwan, Singapore and Japan, this diversification strategy supports the company’s financial health and stability. Founded in 2017 in South Korea, Plcoskin secured a Series B investment on 31 August 2023. Key investors in this round include SJ Investment Partners, WE Ventures, Tony Investment, HG Initiative, Stick Ventures, and Helio Investment. These investments position Plcoskin to continue its innovation and expansion within the Biopharma, Biotechnology, and Health Care industries.

Business keywords: MedTech, reconstructive plastic surgery, regenerative skincare, PCL scaffold, biodegradable material, surgical innovation, cosmeceuticals, therapeutic devices, surgical technology, biomedical engineering, innovative skincare, medical innovation, surgical safety

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 6
SJ Investment Partners, WE Ventures +4
31 Aug 2023
Series A Undisclosed 2
Primer, LOT Vacuum
18 Jan 2021
Seed Round Undisclosed 1
TIPS Program
01 Oct 2020
Seed Round KRW500.00M 1
TiPS
30 Sep 2019
Seed Round KRW400.00M -
30 Aug 2019

Plcoskin Alternatives & Competitors

View All Alternatives
Plcoskin vs
TISSIUM
TISSIUM France

Biomorphic Programmable Polymers

Series D
132 employees
Biotechnology, Health Care
Plcoskin vs

Serica is a growth-stage medical device company focused on the development of silk-based biomaterial...

Series C
15 employees
Biotechnology, Health Care
Plcoskin vs

Advancing the future of maxillofacial tissue regeneration with innovative biological scaffold soluti...

Series A
Biopharma, Biotechnology

FAQ About Plcoskin

Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare.
Plcoskin was founded in 2017.
Plcoskin is headquartered in Korea South.
Plcoskin operates in Biopharma, Biotechnology and Health Care. Its work centres on MedTech, reconstructive plastic surgery, regenerative skincare and PCL scaffold.
Plcoskin has approximately 1 employees.
Plcoskin has completed 5 funding rounds, raising a total of $900.00M. The latest funding stage is Series B.
Top alternatives and competitors to Plcoskin include TISSIUM, Serica, Maybio Matrix, Tepha, Inc., Neuraptive Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Plcoskin and TISSIUM are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Plcoskin, https://bouncewatch.com/company/plcoskin, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout